Baudax Drug Patent Portfolio
Baudax owns 1 orange book drug protected by 8 US patents Given below is the list of Baudax's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10881663 | Method of treating pain in elderly patients with mild renal impairment | 08 Mar, 2039 | Active |
| US11458145 | Methods of administering intravenous meloxicam in a bolus dose | 08 Mar, 2039 | Active |
| US10709713 | Nanoparticulate meloxicam formulations | 26 May, 2030 | Active |
| US11253478 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | 26 May, 2030 | Active |
| US9974746 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | 26 May, 2030 | Active |
| US10463673 | Nanoparticulate meloxicam formulations | 24 Feb, 2024 | Expired |
| US10471067 | Nanoparticulate meloxicam formulations | 24 Feb, 2024 | Expired |
| US8512727 | Nanoparticulate meloxicam formulations | 25 Dec, 2022 | Expired |
Latest Legal Activities on Baudax's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Baudax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jul, 2024 | US10881663 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Jan, 2024 | US10709713 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Nov, 2023 | US10709713 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Aug, 2023 | US10463673 (Litigated) |
| Surcharge for Late Payment, Large Entity | 22 Aug, 2023 | US10463673 (Litigated) |
|
Email Notification
Critical
| 28 Jun, 2023 | US10463673 (Litigated) |
|
Electronic Review
Critical
| 28 Jun, 2023 | US10709713 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2023 | US10709713 |
|
Email Notification
Critical
| 28 Jun, 2023 | US10709713 |
|
Electronic Review
Critical
| 28 Jun, 2023 | US10471067 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2023 | US10463673 (Litigated) |
|
Email Notification
Critical
| 28 Jun, 2023 | US10471067 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2023 | US10471067 (Litigated) |
|
Electronic Review
Critical
| 28 Jun, 2023 | US10463673 (Litigated) |
|
Electronic Review
Critical
| 27 Jun, 2023 | US11458145 |
Baudax's Family Patents
Baudax drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 42.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Baudax Drug List
Given below is the complete list of Baudax's drugs and the patents protecting them.
1. Anjeso
Anjeso is protected by 8 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10881663 | Method of treating pain in elderly patients with mild renal impairment |
08 Mar, 2039
(13 years from now)
| Active |
| US11458145 | Methods of administering intravenous meloxicam in a bolus dose |
08 Mar, 2039
(13 years from now)
| Active |
| US10709713 | Nanoparticulate meloxicam formulations |
26 May, 2030
(4 years from now)
| Active |
| US11253478 | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
26 May, 2030
(4 years from now)
| Active |
| US9974746 | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
26 May, 2030
(4 years from now)
| Active |
| US10463673 | Nanoparticulate meloxicam formulations |
24 Feb, 2024
(1 year, 9 months ago)
| Expired |
| US10471067 | Nanoparticulate meloxicam formulations |
24 Feb, 2024
(1 year, 9 months ago)
| Expired |
| US8512727 | Nanoparticulate meloxicam formulations |
25 Dec, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Anjeso's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List